Synonyms that are in the dictionary are marked in green. Synonyms that are not in the dictionary are marked in red.
Antonyms that are in the dictionary are marked in green. Antonyms that are not in the dictionary are marked in red.
Investing in pre-revenue biotech companies can be tricky.
Source: https://investorplace.com/2023/05/7-stocks-that-wall-street-analysts-are-loving-in-may/
Still in the pre-revenue stage, as it works to turn its solid-state battery technology into a scalable product, current results cannot justify the current market cap of QS stock ($3 billion).
Source: https://investorplace.com/2023/05/qs-stock-latest-spike-is-not-a-buying-signal/
Unfortunately, as a pre-revenue enterprise, short of incurring additional debt, the company must issue new shares of MULN stock.
Source: https://investorplace.com/2023/01/dear-muln-stock-fans-mark-your-calendars-for-jan-25/
While QuantumScape has not yet set a date, the company will release its results for Q2 2023 (ending June 30, 2023) sometime around July 27. As a pre-revenue company, the focus of this release won’t be on QS’s results themselves.
Yes, as a pre-revenue company, LLAP certainly carries elevated risk.
Source: https://investorplace.com/2023/10/3-value-stocks-analysts-predict-will-double-this-year/